These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23237675)

  • 1. Network pharmacology of glioblastoma.
    Aguda BD
    Curr Drug Discov Technol; 2013 Jun; 10(2):125-38. PubMed ID: 23237675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.
    Tuncel G; Kalkan R
    Med Oncol; 2018 Aug; 35(9):122. PubMed ID: 30078108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
    Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
    Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connecting signaling and metabolic pathways in EGF receptor-mediated oncogenesis of glioblastoma.
    Bag AK; Mandloi S; Jarmalavicius S; Mondal S; Kumar K; Mandal C; Walden P; Chakrabarti S; Mandal C
    PLoS Comput Biol; 2019 Aug; 15(8):e1007090. PubMed ID: 31386654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma--a moving target.
    Westermark B
    Ups J Med Sci; 2012 May; 117(2):251-6. PubMed ID: 22512247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toosendanin Exerts an Anti-Cancer Effect in Glioblastoma by Inducing Estrogen Receptor β- and p53-Mediated Apoptosis.
    Cao L; Qu D; Wang H; Zhang S; Jia C; Shi Z; Wang Z; Zhang J; Ma J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated network analysis identifies core pathways in glioblastoma.
    Cerami E; Demir E; Schultz N; Taylor BS; Sander C
    PLoS One; 2010 Feb; 5(2):e8918. PubMed ID: 20169195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients.
    Ganigi PM; Santosh V; Anandh B; Chandramouli BA; Sastry Kolluri VR
    Pediatr Neurosurg; 2005; 41(6):292-9. PubMed ID: 16293948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurrence of Wilson's disease and glioblastoma multiforme--is it a chance association?
    Sinha S; Prashanth LK; Mahadevan A; Satish S; Ravishankar S; Arunodaya GR; Taly AB; Shankar SK
    Clin Neuropathol; 2004; 23(5):241-4. PubMed ID: 15581028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment.
    Agrawal R; Garg A; Benny Malgulwar P; Sharma V; Sarkar C; Kulshreshtha R
    Int J Cancer; 2018 May; 142(9):1817-1828. PubMed ID: 29226333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncovering therapeutic targets for glioblastoma: a systems biology approach.
    Huang PH; Cavenee WK; Furnari FB; White FM
    Cell Cycle; 2007 Nov; 6(22):2750-4. PubMed ID: 17986864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.
    Yu W; Liang S; Zhang C
    Neuromolecular Med; 2018 Dec; 20(4):452-474. PubMed ID: 30182330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.